Latest Product Launch News

AoFrio’s first quarter revenue plunged 28% year-on-year, weighed down by the loss of a major US motor customer amid tariffs. The refrigeration tech firm is banking on new IoT product launches in Q2 to stabilise sales and improve profitability over 2026.

Yowie Group’s June quarter reveals a revenue decline to $1.93 million, offset by improved operating cash inflows and a successful $516,000 capital raise. The company advances product launches in North America and Australia while undergoing significant board restructuring.

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

Regal Partners showcased its diversified $21 billion funds under management and ongoing growth momentum at the Macquarie Australia Conference, emphasising strong inflows, product innovation, and offshore expansion.

Gentrack Group trims its FY26 revenue outlook amid strategic investments and signals a $20 million on-market share buyback post-H1 results.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

FBR Limited secured its first overseas Mantis welding robot sale, launched the Firehawk refractory robot, and expanded its Wall as a Service footprint in Victoria, while navigating a cash balance under $700,000.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Green360 Technologies has kicked off commercial production of its low-carbon Eco-Clay cement alternative through a capital-light tolling agreement with Calix, while securing federal grant funding and a $4.5 million placement to fuel growth.

One Click Group delivered a remarkable 1000% increase in new users and a 64% reduction in acquisition costs in Q1 2026, setting the stage for strong revenue growth ahead of tax season.